SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "LAR1:gu ;mspu:(article);lar1:(liu)"

Sökning: LAR1:gu > Tidskriftsartikel > Linköpings universitet

  • Resultat 941-950 av 1005
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
941.
  • Wallerstedt, Susanna Maria, 1970, et al. (författare)
  • Balancing early access with uncertainties in evidence for drugs authorized by prospective case series - systematic review of reimbursement decisions
  • 2018
  • Ingår i: British Journal of Clinical Pharmacology. - : Wiley. - 0306-5251 .- 1365-2125. ; 84:6, s. 1146-1155
  • Tidskriftsartikel (refereegranskat)abstract
    • AimsTo review clinical and cost-effectiveness evidence underlying reimbursement decisions relating to drugs whose authorization mainly is based on evidence from prospective case series. MethodsA systematic review of all new drugs evaluated in 2011-2016 within a health care profession-driven resource prioritization process, with a market approval based on prospective case series, and a reimbursement decision by the Swedish Dental and Pharmaceutical Benefits Agency (TLV). Public assessment reports from the European Medicines Agency, published pivotal studies, and TLV, Scottish Medicines Consortium and National Institute of Health and Care Excellence decisions and guidance documents were reviewed. ResultsSix drug cases were assessed (brentuximab vedotin, bosutinib, ponatinib, idelalisib, vismodegib, ceritinib). The validity of the pivotal studies was hampered by the use of surrogate primary outcomes and the absence of recruitment information. To quantify drug treatment effect sizes, the reimbursement agencies primarily used data from another source in indirect comparisons. TLV granted reimbursement in five cases, compared with five in five cases for Scottish Medicines Consortium and four in five cases for National Institute of Health and Care Excellence. Decision modifiers, contributing to granted reimbursement despite hugely uncertain cost-effectiveness ratios, were, for example, small population size, occasionally linked to budget impact, severity of disease, end of life and improved life expectancy. ConclusionFor drugs whose authorization is based on prospective case series, most applications for reimbursement within public health care are granted. The underlying evidence has limitations over and above the design per se, and decision modifiers are frequently referred to in the value-based pricing decision making.
  •  
942.
  • Wallerstedt, Susanna Maria, 1970, et al. (författare)
  • Evidence synthesis based on non-randomised studies-a critical review of studies leading to conclusions on fall risk properties of loop diuretics/beta-blockers
  • 2019
  • Ingår i: European Journal of Clinical Pharmacology. - : Springer Science and Business Media LLC. - 0031-6970 .- 1432-1041. ; 75:12, s. 1731-1738
  • Tidskriftsartikel (refereegranskat)abstract
    • Purpose To describe methodological and reporting issues in non-randomised comparative drug safety studies pooled in meta-analyses, with focus on confounding by indication. Methods All studies included in statistically significant meta-analyses in a recent publication investigating fall risk properties of cardiovascular drugs were reviewed. Study characteristics were extracted and assessed. Results Nine studies, including between 498 and 321,995 individuals, contributed data to the significant meta-analyses in which loop diuretics and beta-blockers were associated with falls, five published in 2015. Five individual studies reported a statistically significant association. In the five cohort studies, characteristics of exposed vs unexposed individuals were either not reported (n = 3) or differed substantially regarding morbidity (n = 2). Drug treatment was determined at baseline, and data on falls were collected for up to 2 years thereafter. Out of the four case-control studies, the cases and controls in only one study were matched for morbidity. Morbidity characteristics of fallers compared with non-fallers were either not reported (n = 2) or they differed (n = 1) or were reported according to the matched-for diseases (n = 1). Confounding by indication was explicitly discussed in two studies. None of the abstract conclusions considered causality issues or the possibility of confounding by indication. Conclusions Confounding by indication is a major issue in non-randomised comparative drug safety studies, a problem which may be concealed in meta-analyses. To enhance such research, compared groups need to be balanced regarding relevant factors including morbidities and characteristics adequately reported. Confounding by indication needs to be explicitly discussed and highlighted in the abstract conclusion.
  •  
943.
  • Wallerstedt, Susanna Maria, 1970, et al. (författare)
  • Methodological issues in research on drug-related admissions: A meta-epidemiological review with focus on causality assessments
  • 2022
  • Ingår i: British Journal of Clinical Pharmacology. - : Wiley. - 0306-5251 .- 1365-2125. ; 88:2, s. 541-550
  • Tidskriftsartikel (refereegranskat)abstract
    • Aim To investigate methodological aspects potentially related to the diverging scientific literature on the prevalence of drug-related hospitalisations, focusing on causality assessments. Methods Original studies contributing data to a recent meta-analysis were reviewed. Methodological aspects, in particular those related to causality assessments, were extracted and compiled. Results Thirteen studies provided data on the prevalence of drug-related admissions. Seven studies focused on adverse drug reactions (prevalences 1.3-10%), and six studies used the broader concept of drug-related problems (prevalences 4.5-41%). In 10 out of 13 studies, causality between the drug and the specified problem was assessed. One study required a probable causal relationship; the remaining studies merely required a possible causal relationship. Five studies assessed the association between the problem assumed to be related to drug therapy and the admission, at one end requiring the former to be demonstrated as the underlying cause and, at the other, merely requiring a temporal relationship between drug intake and admission. Three out of eight studies involving multiple assessors for all/some cases reported the inter-rater agreement, ranging from none to almost perfect. Physicians were involved in the assessments in five studies, reporting prevalences of 3.2% to 4.5%, while studies without such medical input reported prevalences of 8.8% to 41%. Conclusions This review illustrates that methodological issues contribute to the diverse literature on drug-related admissions. We provide suggestions for harmonisation of research, including explicitly assessing the drug-problem-admission relationships from a medical perspective, focusing on problems where the drug treatment is the probable culprit.
  •  
944.
  • Wallin, Anders, 1950, et al. (författare)
  • Donepezil in Alzheimer's disease : What to expect after 3 years of treatment in a routine clinical setting
  • 2007
  • Ingår i: Dementia and Geriatric Cognitive Disorders. - Basel : S. Karger AG. - 1420-8008 .- 1421-9824. ; 23:3, s. 150-160
  • Tidskriftsartikel (refereegranskat)abstract
    • Background/Aims: Clinical short-term trails have shown positive effects of donepezil treatment in patients with Alzheimer's disease. The outcome of continuous long-term treatment in the routine clinical settings remains to be investigated. Methods: The Swedish Alzheimer Treatment Study (SATS) is a descriptive, prospective, longitudinal, multicentre study. Four hundred and thirty-five outpatients with the clinical diagnosis of Alzheimer's disease, received treatment with donepezil. Patients were assessed with Mini-Mental State Examination (MMSE), Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog), global rating (CIBIC) and Instrumental Activities of Daily Living (IADL) at baseline and every 6 months for a total period of 3 years. Results: The mean MMSE change from baseline was positive for more than 6 months and in subgroups of patients for 12 months. After 3 years of treatment the mean change from baseline in MMSE-score was 3.8 points (95% CI, 3.0-4.7) and the ADAS-cog rise was 8.2 points (95% CI, 6.4-10.1). This is better than expected in untreated historical cohorts, and better than the ADAS-cog rise calculated by the Stern equation (15.6 points, 95% CI, 14.5-16.6). After 3 years with 38% of the patients remaining, 30% of the them were unchanged or improved in the global assessment. Conclusion: Three-year donepezil treatment showed a positive global and cognitive outcome in the routine clinical setting. Copyright © 2007 S. Karger AG.
  •  
945.
  •  
946.
  • Wallin, Sofia, et al. (författare)
  • Implementing data on targeted therapy from the INFORM registry platform for children with relapsed cancer in Sweden
  • 2024
  • Ingår i: FRONTIERS IN ONCOLOGY. - : FRONTIERS MEDIA SA. - 2234-943X. ; 14
  • Tidskriftsartikel (refereegranskat)abstract
    • Background Advances in treatment of childhood malignancies have improved overall cure rates to 80%. Nevertheless, cancer is still the most common cause of childhood mortality in Sweden. The prognosis is particularly poor for relapse of high-risk malignancies. In the international INFORM registry, tumor tissue from patients with relapsed, refractory, or progressive pediatric cancer as well as from very-high risk primary tumors is biologically characterized using next-generation sequencing to identify possible therapeutic targets. We analyzed data from Swedish children included in the INFORM registry concerning patient characteristics, survival, sequencing results and whether targeted treatment was administered to the children based on the molecular findings.Methods A registry-based descriptive analysis of 184 patients included in the INFORM registry in Sweden during 2016-2021.Results The most common diagnoses were soft tissue and bone sarcomas followed by high grade gliomas [including diffuse intrinsic pontine glioma (DIPG)]. Complete molecular analysis was successful for 203/212 samples originating from 184 patients. In 88% of the samples, at least one actionable target was identified. Highly prioritized targets, according to a preset scale, were identified in 48 (24%) samples from 40 patients and 24 of these patients received matched targeted treatment but only six children within a clinical trial. No statistically significant benefit in terms of overall survival or progression free survival was observed between children treated with matched targeted treatment compared to all others.Conclusion This international collaborative study demonstrate feasibility regarding sequencing of pediatric high-risk tumors providing molecular data regarding potential actionable targets to clinicians. For a few individuals the INFORM analysis was of utmost importance and should be regarded as a new standard of care with the potential to guide targeted therapy.
  •  
947.
  • Wang, Hui, et al. (författare)
  • A pathway-based approach to find novel markers of local glucocorticoid treatment in intermittent allergic rhinitis
  • 2011
  • Ingår i: Allergy. European Journal of Allergy and Clinical Immunology. - : Wiley-Blackwell. - 0105-4538 .- 1398-9995. ; 66:1, s. 132-140
  • Tidskriftsartikel (refereegranskat)abstract
    • BACKGROUND: Glucocorticoids (GCs) may affect the expression of hundreds of genes in different cells and tissues from patients with intermittent allergic rhinitis (IAR). It is a formidable challenge to understand these complex changes by studying individual genes. In this study, we aimed to identify (i) pathways affected by local GC treatment and (ii) examine if those pathways could be used to find novel markers of local GC treatment in nasal fluids from patients with IAR. METHODS: Gene expression microarray- and iTRAQ-based proteomic analyses of nasal fluids, nasal fluid cells and nasal mucosa from patients with IAR were performed to find pathways enriched for differentially expressed genes and proteins. Proteins representing those pathways were analyzed with ELISA in an independent material of nasal fluids from 23 patients with IAR before and after treatment with a local GC. RESULTS: Transcriptomal and proteomic high-throughput analyses of nasal fluids, nasal fluid cells and nasal mucosal showed that local GC treatment affected a wide variety of pathways in IAR such as the glucocorticoid receptor pathway and the acute phase response pathway. Extracellular proteins encoded by genes in those pathways were analyzed in an independent material of nasal fluids from patients. Proteins that changed significantly in expression included known biomarkers such as eosinophil cationic protein but also proteins that had not been previously described in IAR, namely CCL2, M-CSF, CXCL6 and apoH. CONCLUSION: Pathway-based analyses of genomic and proteomic high-throughput data can be used as a complementary approach to identify novel potential markers of GC treatment in IAR.
  •  
948.
  •  
949.
  • Wang, Hui, et al. (författare)
  • Identification of novel biomarkers in seasonal allergic rhinitis by combining proteomic, multivariate and pathway analysis
  • 2011
  • Ingår i: Plos ONE. - : Public Library of Science (PLoS). - 1932-6203. ; 6:8
  • Tidskriftsartikel (refereegranskat)abstract
    • Abstract BACKGROUND: Glucocorticoids (GCs) play a key role in the treatment of seasonal allergic rhinitis (SAR). However, some patients show a low response to GC treatment. We hypothesized that proteins that correlated to discrimination between symptomatic high and low responders (HR and LR) to GC treatment might be regulated by GCs and therefore suitable as biomarkers for GC treatment. METHODOLOGY/PRINCIPAL FINDINGS: We identified 953 nasal fluid proteins in symptomatic HR and LR with a LC MS/MS based-quantitative proteomics analysis and performed multivariate analysis to identify a combination of proteins that best separated symptomatic HR and LR. Pathway analysis showed that those proteins were most enriched in the acute phase response pathway. We prioritized candidate biomarkers for GC treatment based on the multivariate and pathway analysis. Next, we tested if those candidate biomarkers differed before and after GC treatment in nasal fluids from 40 patients with SAR using ELISA. Several proteins including ORM (P<0.0001), APOH (P<0.0001), FGA (P<0.01), CTSD (P<0.05) and SERPINB3 (P<0.05) differed significantly before and after GC treatment. Particularly, ORM (P<0.01), FGA (P<0.05) and APOH (P<0.01) that belonged to the acute phase response pathway decreased significantly in HR but not LR before and after GC treatment. CONCLUSIONS/SIGNIFICANCE: We identified several novel biomarkers for GC treatment response in SAR with combined proteomics, multivariate and pathway analysis. The analytical principles may be generally applicable to identify biomarkers in clinical studies of complex diseases.
  •  
950.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 941-950 av 1005
Typ av publikation
Typ av innehåll
refereegranskat (979)
övrigt vetenskapligt/konstnärligt (19)
populärvet., debatt m.m. (7)
Författare/redaktör
Kjellgren, Karin I, ... (30)
Tengvall, Pentti (29)
Blennow, Kaj, 1958 (20)
Willander, Magnus (20)
Zetterberg, Henrik, ... (19)
Olausson, Håkan, 196 ... (19)
visa fler...
Ludvigsson, Johnny (17)
Dahlström, Ulf (16)
Fu, Michael, 1963 (15)
Steineck, Gunnar, 19 ... (14)
Heimann, Mikael, 195 ... (14)
Willander, Magnus, 1 ... (13)
Wang, Hui (13)
Öberg, Birgitta (13)
Heimann, Mikael (12)
Fejes, Andreas, 1977 ... (11)
Aspenberg, Per (11)
Garcia, Danilo, 1973 (11)
Hansson, Sverker, 19 ... (10)
Wessberg, Johan, 196 ... (10)
Olausson, Håkan (10)
Croy, Ilona (10)
Lind, Marcus, 1976 (10)
Klason, Peter, 1977 (10)
Åvall-Lundqvist, Eli ... (10)
Rosengren, Annika, 1 ... (9)
Thomsen, Peter, 1953 (9)
Svensson, Lennart (9)
Martinsson, Peter, 1 ... (9)
Nour, Omer (9)
Wennergren, Göran, 1 ... (8)
Benson, Mikael (8)
Jönsson, Anna K (8)
Pivodic, Aldina, 197 ... (8)
Jaarsma, Tiny (7)
Petzold, Max, 1973 (7)
Karlsson, Jón, 1953 (7)
Borga, Magnus (7)
Wasling, Helena Back ... (7)
Bernhardsson, Susann ... (7)
Stalfors, Joacim, 19 ... (7)
Hägg, Staffan (7)
Lissner, Lauren, 195 ... (7)
Elfvin, Anders, 1971 (7)
Bergh, Christina, 19 ... (7)
Åkesson, Karin (7)
Dunberger, Gail (7)
Gerdle, Björn (7)
Spak, Fredrik, 1948 (7)
Bendtsen, Preben (7)
visa färre...
Lärosäte
Göteborgs universitet (1005)
Språk
Engelska (983)
Svenska (21)
Spanska (1)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (752)
Samhällsvetenskap (173)
Naturvetenskap (119)
Teknik (32)
Humaniora (25)
Lantbruksvetenskap (6)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy